In vivo, paroxetine has been described to improve LV function and structure and to reverse or even ameliorate several features related to cardiac dysfunction in a mouse model of myocardial infarct when compared with fluoxetine, a structural analog unable to inhibit GRK2 but with SSRI capacity (Schumacher et al., 2015). Here, GRK2 is linked to myocardial infarction.